These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19632959)

  • 1. HIV-1 meningoencephalitis in patients on effective HAART.
    Lafeuillade A; Cheret A; Hittinger G; Poggi C
    HIV Clin Trials; 2009; 10(3):200-2. PubMed ID: 19632959
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-HCV Co-infection therapeutic outcomes have not improved over time.
    Cooper C; Costiniuk C; Giguère P
    HIV Clin Trials; 2009; 10(3):203-6. PubMed ID: 19632960
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.
    De Socio GV; Martinelli L; Zazzi M; Baldelli F
    Clin Infect Dis; 2008 Jun; 46(12):1938. PubMed ID: 18540815
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication.
    Wendel KA; McArthur JC
    Clin Infect Dis; 2003 Oct; 37(8):1107-11. PubMed ID: 14523776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?
    Gavazzi G; Bouchard O; Leclercq P; Morel-Baccard C; Bosseray A; Dutertre N; Micoud M; Morand P
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1021-3. PubMed ID: 10933615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?
    Bani-Sadr F; Goderel I; Morand P; Payan C; Lunel F; Pol S; Perronne C; Carrat F; Cacoub P
    AIDS; 2007 Jul; 21(12):1645-8. PubMed ID: 17630563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
    Weissbrich B; Langmann P; Schubert J; Jassoy C; Klinker H
    Eur J Med Res; 2003 Nov; 8(11):495-8. PubMed ID: 14644704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes.
    Vinuesa D; Parra-Ruiz J; Chueca N; Alvarez M; Muñoz-Medina L; Garcia F; Hernandez-Quero J
    AIDS; 2014 Jul; 28(12):1835-7. PubMed ID: 24835357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does HAART improve renal function? An association between serum cystatin C concentration, HIV viral load and HAART duration.
    Jaroszewicz J; Wiercinska-Drapalo A; Lapinski TW; Prokopowicz D; Rogalska M; Parfieniuk A
    Antivir Ther; 2006; 11(5):641-5. PubMed ID: 16964834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
    Orbea Ríos L; Domínguez Castellanos A; Justo Alpañés E
    An Med Interna; 2002 Jun; 19(6):321-2. PubMed ID: 12152394
    [No Abstract]   [Full Text] [Related]  

  • 15. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    HIV Med; 2007 Mar; 8(2):80-5. PubMed ID: 17352763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
    Ceballos-Salobreña A; Gaitán-Cepeda LA; Ceballos-Garcia L; Lezama-Del Valle D
    AIDS Patient Care STDS; 2000 Dec; 14(12):627-35. PubMed ID: 11119429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence.
    Jordan J; Cahn P; Goebel F; Matheron S; Bradley C; Woodcock A
    AIDS Patient Care STDS; 2005 Jan; 19(1):9-18. PubMed ID: 15665631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching HIV therapies: competing host and viral factors.
    Kilby JM
    Lancet; 2010 Jan; 375(9712):352-4. PubMed ID: 20074790
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma exchange significantly affects darunavir exposure.
    Garcia M; Le Moal G; Dupuis A; Rochette N; Roblot F; Venisse N
    J Antimicrob Chemother; 2014 Aug; 69(8):2296-7. PubMed ID: 24722841
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.